Solutions Case Studies
Download DocumentApplication of ACTIVTox® screening results to evaluate toxic profiles
Liver toxicity is a common cause of failure in new drug development. A system for predictive hepatotoxicology for use in the design of new screening campaigns and optimizing leads could dramatically reduce the time and cost of drug development.
Any such system consists of three essential parts: a reliable human hepatotoxicity model, a database of compounds that have been screened in the system and software to collate the data, find similarities and make predictions. ACTIVTox® is an hepatocyte-based system coupling a human liver cell line with simple, rugged assays for hepatotoxicity, such as LDH release. MDL software provides a series of modules, such as MDL® Assay Explorer, that can be used to manage screening campaigns as well as visualize the results.
Together, MDL and Amphioxus Cell Technologies are creating a database of compounds tested in a variety of toxicity assays providing a framework in which to examine the structural basis of liver toxicity. This tool has the unique attribute that proprietary compounds can be screened in the same experimental system and added to the database, creating a customized environment for lead optimization.
For more information on Amphioxus Cell Technologies and ACTIVTox® please visit www.amphioxus.com.
To read the complete case study, click the Download Document link near the top of the this article.
